Bind banks $12.4M round as lead program heads into PhI

In the beginning of the year, when Cambridge, MA-based Bind Biosciences took the wraps off an $11 million round, the biotech company aroused considerable interest in the venture community. That interest helped spur a follow-up round for another $12.4 million in a Series C-1, which the developer is announcing today as it pushes ahead on active partnering talks--with one pact already quietly inked. "The prior round was oversubscribed in January," CEO Scott Minick tells FierceBiotech. "A...